A Randomized Phase 3 trial of Nivolumab (NSC# 748726 IND# 125462) in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma.

Closed

Phase

Abbreviated Title

Randomized ph III study of Nivo + chemo-immunotherapy for newly dx primary mediastinal B-lymph

Status Notes

CTSU/ANHL1931 was closed to accrual, effective 05/28/25.
CTSU/ANHL1931 has been endorsed and activated by SWOG, effective 7/15/21. CTSU/ANHL1931 was activated by Children's Oncology Group, effective 6/7/21.

Activated

06/07/2021

Participants

ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS LISTED ON TITLE PAGE

Research committees

Lymphoma

Treatment

Cyclophosphamide Prednisone Vincristine Doxorubicin Etoposide Rituximab Nivolumab

Eligibility Criteria Expand/Collapse

Eligibility criteria are accessible from the protocol abstract page on the CTSU website (http://www.ctsu.org).

Other Clinical Trials

SWOG Clinical Trial Number

CTSU/EA4232

A Randomized Phase III Study to Evaluate Benefits of Autologous Stem Cell Transplant in Patients with Peripheral T Cell Lymphoma That Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)

Research Committee(s)

Lymphoma

Activated

01/30/2025

Open

Phase

SWOG Clinical Trial Number

S2308

Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma

Research Committee(s)

Lymphoma

Activated

08/01/2024

Accrual

37%

Open

Phase

SWOG Clinical Trial Number

S2207

Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapse/Refractory Large B-Cell Lymphoma

Research Committee(s)

Lymphoma

Activated

06/30/2023

Accrual

14%

Open

Phase